**Supplemental Figure 1. Selection steps flowchart of patients included in the current analysis, the HIV Outpatient Study 2007-2018, N=736.**

Patients (Pts) in HOPS database as of June 30, 2019

(n=11,179)

Pts who switched to INSTI regimen (n=2,189)

Pts who switched to non-INSTI regimen (n=1,894)

Pts virally suppressed during 1 year before switch (n=1,031)

Pts virally suppressed during 1 year before switch (n=737)

Pts virally suppressed while on INSTI regimen (n=737)

Pts virally suppressed while on non-INSTI regimen (n=443)

Pts with ≥ 2 BMI one year before switch (n=443)

Pts with ≥ 2 BMI one year before switch (n=413)

Pts with BMI at switch (n=556)

Pts with BMI at switch (n=374)

Pts with ≥1 BMI after switch (n=525)

Pts with ≥1 BMI after switch (n=347)

Pts with ≥6 months observation on INSTI regimen (n=472)

Pts with ≥6 months observation on non-INSTI regimen (n=305)

Pts with ≥ 6 months observation before switch (n=441)

Pts with ≥6 months observation before switch (n=295)

Pts consented by December 31, 2018

(n=11,111)

 Pts who received ART after FDA approval of raltegravir on October 12, 2007 (n=7,054)

Pts participating at active HOPS sites

(n=9,246)

Note: baseline is defined as time of ART switch; virally suppressed is HIV viral load <200 copies/mL; active HOPS sites are clinics that are open and actively recruiting patients and following patients in HOPS.

Abbreviations: BMI, body mass index; INSTI, integrase strand transfer inhibitor